There are 2185 resources available
381P - Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience
Presenter: Kelsey Natsuhara
Session: Poster session 15
Resources:
Abstract
1443P - Association between fruquintinib-induced hypertension and clinical outcomes from FRUTIGA, a phase III study of fruquintinib plus paclitaxel in previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Presenter: Shukui Qin
Session: Poster session 18
Resources:
Abstract
382P - Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study
Presenter: Jiaxuan Liu
Session: Poster session 15
Resources:
Abstract
1444P - Nature trumps nurture: Squamous cell carcinoma remains the leading cause of esophageal cancer in Asian-Americans
Presenter: Shubham Gulati
Session: Poster session 18
Resources:
Abstract
383P - Clinical experience with TTX-MC138: A first-in-class therapy against metastatic cancer
Presenter: Andreas Varkaris
Session: Poster session 15
Resources:
Abstract
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract
384P - Disitamab vedotin (RC48) for previously treated HER2-expressing metastatic breast cancer with abnormal activation of PAM pathway: Results from a single-arm, prospective phase II clinical trial
Presenter: Yun Wu
Session: Poster session 15
Resources:
Abstract
1446P - Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial
Presenter: Huiwen Miao
Session: Poster session 18
Resources:
Abstract
385P - A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
Presenter: David Page
Session: Poster session 15
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
Resources:
Abstract